Sangamo Therapeutics, Inc.
SGMO
$0.14
$0.000.22%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 88.43% | -98.82% | 5,042.13% | 1,238.25% | 269.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 88.43% | -98.82% | 5,042.13% | 1,238.25% | 269.78% |
| Cost of Revenue | 33.92% | 1.48% | 11.81% | -30.89% | -53.89% |
| Gross Profit | -8.08% | -227.13% | 63.22% | 48.12% | 67.41% |
| SG&A Expenses | -21.37% | -9.68% | -36.28% | -14.52% | -25.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.56% | -1.22% | -6.00% | -26.84% | -47.99% |
| Operating Income | 3.19% | -377.09% | 53.15% | 39.74% | 58.45% |
| Income Before Tax | -59.39% | -426.12% | 44.64% | 37.79% | 60.67% |
| Income Tax Expenses | -29.51% | -282.95% | -63.51% | 21.43% | -56.99% |
| Earnings from Continuing Operations | -59.94% | -427.31% | 44.68% | 37.67% | 61.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.94% | -427.31% | 44.68% | 37.67% | 61.20% |
| EBIT | 3.19% | -377.09% | 53.15% | 39.74% | 58.45% |
| EBITDA | 2.20% | -346.02% | 54.27% | 40.12% | 59.25% |
| EPS Basic | 0.45% | -355.11% | 54.45% | 48.97% | 67.22% |
| Normalized Basic EPS | 34.76% | -285.35% | 57.31% | 46.28% | 67.06% |
| EPS Diluted | 4.40% | -387.00% | 54.45% | 48.97% | 65.86% |
| Normalized Diluted EPS | 34.76% | -290.74% | 57.31% | 46.28% | 67.06% |
| Average Basic Shares Outstanding | 60.68% | 46.04% | 25.99% | 22.14% | 18.33% |
| Average Diluted Shares Outstanding | 60.68% | 41.97% | 25.99% | 22.14% | 18.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |